SCHEMBL509934

SCHEMBL509934

NC(CC(=O)[O-])C(CC(=O)[O-])(CC(=O)[O-])NCC(=O)[O-].[Ca+2].[Na+].[Na+]

nearest known ligand 0.32

Known targets — ChEMBL curated mechanism

GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.32
CA4 P22748 2/20 0.31
CPT2 P23786 1/20 0.31
CPT1A P50416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL2170087 0.98 CA2 (0.31) CA2CA4CPT2CPT1A
SCHEMBL1389543 0.98 CA2 (0.33) CA2CA4CPT2CPT1A
Water SCHEMBL11495893 0.97 CA2 (0.32) CA2CA4CPT2CPT1A
SCHEMBL11099372 0.97 CA2 (0.32) CA2CA4CPT2CPT1A
Water SCHEMBL976877 0.97 CA2 (0.32) CA2CA4CPT2CPT1A
SCHEMBL7149875 0.97 CA4 (0.35) CA2CA4CPT2CPT1A
Water SCHEMBL9243946 0.97 CA2 (0.32) CA2CA4CPT2CPT1A
Water SCHEMBL8963366 0.95 CA4 (0.34) CA2CA4CPT2CPT1A
Water SCHEMBL8030606 0.95 CA4 (0.34) CA2CA4CPT2CPT1A
SCHEMBL11131358 0.95 CPT2 (0.32) CPT2CPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250033986-A1 EXTRUSION-ENCAPSULATED CALCIUM SALTS AS OPACIFYING/WHITENING AGENTS CAPOL INC. (CA) 2025-01-30 US claimed
US-10653139-B2 Device for stored products protection and uses thereof UNIVERSIDADE DO PORTO (PT) 2020-05-19 US claimed
US-20180310556-A1 DEVICE FOR STORED PRODUCTS PROTECTION AND USES THEREOF UNIVERSIDADE DO PORTO (PT) 2018-11-01 US claimed
EP-3367793-A1 DEVICE FOR STORED PRODUCTS PROTECTION AND USES THEREOF Universidade do Porto (PT) 2018-09-05 EP claimed
WO-2017072563-A1 DEVICE FOR STORED PRODUCTS PROTECTION AND USES THEREOF UNIVERSIDADE DO PORTO (PT) 2017-05-04 WO claimed
EP-3107408-A1 ENCAPSULATED SOFT FOOD COMPOSITIONS AND METHODS OF MAKING Incredible Foods, Inc. (US) 2016-12-28 EP claimed
WO-2015127063-A1 ENCAPSULATED SOFT FOOD COMPOSITIONS AND METHODS OF MAKING WIKIFOODS, INC. (US) 2015-08-27 WO claimed
JP-4173098-A None JP disclosed
US-20260110140-A1 PACKAGING ITEM NOTPLA LTD (GB) 2026-04-23 US disclosed
US-12485091-B2 Controlled release core-shell particles and suspensions including the same Nulixir Inc. (US) 2025-12-02 US disclosed
US-20250302823-A1 COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS DISC MEDICINE, INC. 2025-10-02 US disclosed
US-12350367-B2 Particles for administration of active ingredients and methods of making the same Nulixir Inc. (US) 2025-07-08 US disclosed
EP-4531854-A1 COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS Disc Medicine, Inc. (US) 2025-04-09 EP disclosed
WO-2006041469-A1 PRESERVATIVE SYSTEMS FOR EXTENDING SHELF LIFE OF FOOD INTERMEDIATES THROUGH MICROBIAL AND ENZYMATIC CONTROL IN N0N-MODIFIED ATMOSPHERE GENERAL MILLS MARKETING, INC. (US) 2006-04-20 WO disclosed
US-5641533-A SEMI-GELLED SYSTEM CONTAINING ATLEAST ONE LOW METHOXYPECTIN WITH SPECIFIC DEGREE OF ESTERIFICATION AND AMIDATION TO REPLACE ALL OR A PART OF FAT IN MAYONNAISE HERCULES INCORPORATED (US) 1997-06-24 US disclosed
US-5626901-A DIETETICS USING AMIDATED GALACTURONIC ACID METHYL ESTER IN WATER FOR FAT REPLACEMENTS HERCULES INCORPORATED (US) 1997-05-06 US disclosed
EP-0758531-A2 No and low fat majonnaise compositions HERCULES INCORPORATED (US) 1997-02-19 EP disclosed
EP-0757895-A2 No and low fat salad dressing compositions HERCULES INCORPORATED (US) 1997-02-12 EP disclosed
JP-H04173098-A PREVENTION OF COLOR DEVELOPMENT OF COLOR REAGENT FOR PEROXIDASE DURING STORAGE AND COLOR REAGENT FOR PEROXIDASE UTILIZING THE SAME METHOD FUNAYAMA MASASHI 1992-06-19 JP disclosed
US-4425367-A MICROCRYSTALLINE CELLULOSE, SHELF LIFE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1984-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302823-A1 COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS SLC10A1, GFPT1, GLS2 CA2 531/4885CA4 1124/4885CPT2 550/4885
US-20260110140-A1 PACKAGING ITEM AGL, PWWP2B, GHDC CA2 4650/4885CA4 4374/4885CPT2 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.